Stallergenes slapped with injunction

There are still issues with Stallergenes Greer’s factory in Antony, the Agence Nationale de Sécurité du Médicament has concluded.
Photo: Stallergenes Greer / PR
Photo: Stallergenes Greer / PR
by marketwire, translated by catherine brett

The French healthcare inspection agency, Agence Nationale de Sécurité du Médicament (ANSM), has issued an injunction against Stallergenes Greer after an inspection of its factory in Antony, Nordea writes in an analysis.

According to the Nordic bank, the authorities inspected the factory in February and found significant shortcomings.

Nordea assesses that Stallergenes will avoid the factory being shut down, but that this prediction is not entirely certain.

Back in 2015, Stallergenes Greer received another injunction regarding the same factory, which led to a long production halt and large-scale product recalls.

ALK generated extra sales in the French market during that period.

ALK expects to have approved peanut allergy vaccine in 2030

ALK to start phase I trial of peanut allergy tablet vaccine

Stallergenes bets big on personalized allergy treatment, enters another research collaboration

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading